Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Preferred Stock Liabilities (2016 - 2017)

VYNE Therapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $50.3 million for Q4 2017.

  • For Q4 2017, Preferred Stock Liabilities rose 12.28% year-over-year to $50.3 million; the TTM value through Dec 2017 reached $50.3 million, up 12.28%, while the annual FY2017 figure was $50.3 million, 12.28% up from the prior year.
  • Preferred Stock Liabilities reached $50.3 million in Q4 2017 per VYNE's latest filing, up from $44.8 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $50.3 million in Q4 2017 to a low of $44.8 million in Q4 2016.